OBJECTIVE: To test the safety and immunogenicity of two doses of autoclaved L. major (ALM) vaccine mixed with BCG. SETTING:Kala-azar endemic area of eastern Sudan. DESIGN: This was a randomised, double blind and BCG controlled phase I/II study. SUBJECTS:Eighty healthy volunteers (forty children and forty adults) with no past history of kala-azar, no reactivity to leishmanin antigen and with a reciprocal direct agglutination test (DAT) titre of <200 were recruited. Informed consents were obtained from volunteers or their guardians in case of children. MAIN OUTCOME MEASURES: Conversion in the leishmanin skin and the DAT tests. INTERVENTION: Two intra-dermal injections of either ALM+BCG or BCG alone. The injections were three weeks apart. RESULTS:Side effects were minimal and confined to the injection site, with no significant difference between the ALM+BCG and the BCG alone groups. The leishmanin skin conversion was significantly higher in the ALM+BCG group compared to the BCG alone group (p<0.0005). Furthermore, the Leishmanin skin test conversion was significantly higher in children than adults (p<0.0005). One adult volunteer in the ALM+BCG group converted in both the Leishmanin skin and the DAT tests. CONCLUSION: We conclude that two doses of ALM+BCG are safe and immunogenic, especially in children.
RCT Entities:
OBJECTIVE: To test the safety and immunogenicity of two doses of autoclaved L. major (ALM) vaccine mixed with BCG. SETTING: Kala-azar endemic area of eastern Sudan. DESIGN: This was a randomised, double blind and BCG controlled phase I/II study. SUBJECTS: Eighty healthy volunteers (forty children and forty adults) with no past history of kala-azar, no reactivity to leishmanin antigen and with a reciprocal direct agglutination test (DAT) titre of <200 were recruited. Informed consents were obtained from volunteers or their guardians in case of children. MAIN OUTCOME MEASURES: Conversion in the leishmanin skin and the DAT tests. INTERVENTION: Two intra-dermal injections of either ALM+BCG or BCG alone. The injections were three weeks apart. RESULTS: Side effects were minimal and confined to the injection site, with no significant difference between the ALM+BCG and the BCG alone groups. The leishmanin skin conversion was significantly higher in the ALM+BCG group compared to the BCG alone group (p<0.0005). Furthermore, the Leishmanin skin test conversion was significantly higher in children than adults (p<0.0005). One adult volunteer in the ALM+BCG group converted in both the Leishmanin skin and the DAT tests. CONCLUSION: We conclude that two doses of ALM+BCG are safe and immunogenic, especially in children.
Authors: Eduardo Antonio Ferraz Coelho; Carlos Alberto Pereira Tavares; Karla de Melo Lima; Célio Lopes Silva; José Maciel Rodrigues; Ana Paula Fernandes Journal: Parasitol Res Date: 2006-01-24 Impact factor: 2.289
Authors: Ken Stuart; Reto Brun; Simon Croft; Alan Fairlamb; Ricardo E Gürtler; Jim McKerrow; Steve Reed; Rick Tarleton Journal: J Clin Invest Date: 2008-04 Impact factor: 14.808
Authors: Mona E E Elfaki; Eltahir A G Khalil; Anne S De Groot; Ahmed M Musa; Andres Gutierrez; Brima M Younis; Kawthar A M Salih; Ahmed M El-Hassan Journal: Hum Vaccin Immunother Date: 2012-08-24 Impact factor: 3.452
Authors: Felicitat Todolí; Laia Solano-Gallego; Rafael de Juan; Pere Morell; Maria Del Carmen Núñez; Rodrigo Lasa; Silvia Gómez-Sebastián; José M Escribano; Jordi Alberola; Alhelí Rodríguez-Cortés Journal: Am J Trop Med Hyg Date: 2010-12 Impact factor: 2.345